Stem Cell Research & Therapy (Feb 2019)

Preconditioning human natural killer cells with chorionic villous mesenchymal stem cells stimulates their expression of inflammatory and anti-tumor molecules

  • M. H. Abumaree,
  • N. A. Alshehri,
  • A. Almotery,
  • A. M. Al Subayyil,
  • E. Bahattab,
  • F. M. Abomaray,
  • T. Khatlani,
  • B. Kalionis,
  • D. Jawdat,
  • M. F. El-Muzaini,
  • M. A. Al Jumah,
  • A. S. AlAskar

DOI
https://doi.org/10.1186/s13287-019-1153-9
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Background Mesenchymal stem cells derived from the chorionic villi of human placentae (pMSCs) produce a unique array of mediators that regulate the essential cellular functions of their target cells. These properties make pMSCs attractive candidates for cell-based therapy. Here, we examined the effects of culturing human natural killer (NK) cells with pMSCs on NK cell functions. Methods pMSCs were cultured with IL-2-activated and non-activated NK cells. NK cell proliferation and cytolytic activities were monitored. NK cell expression of receptors mediating their cytolytic activity against pMSCs, and the mechanisms underlying this effect on pMSCs, were also investigated. Results Our findings show that IL-2-activated NK cells, but not freshly isolated NK cells, efficiently lyse pMSCs and that this response might involve the activating NK cell receptor CD69. Interestingly, although pMSCs expressed HLA class I molecules, they were nevertheless lysed by NK cells, suggesting that HLA class I antigens do not play a significant role in protecting pMSCs from NK cell cytolytic activity. Co-culturing NK cells with pMSCs also inhibited NK cell expression of receptors, including CD69, NKpG2D, CD94, and NKp30, although these co-cultured NK cells were not inhibited in lysing cancer cells in vitro. Importantly, co-cultured NK cells significantly increased their production of molecules with anti-tumor effects. Conclusions These findings suggest that pMSCs might have potential applications in cancer therapy.

Keywords